Introduction and Objective: The rates of screening for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis-4 (FIB-4) index is slowly increasing in the primary care setting. Access to Vibration-Controlled Transient Elastography (FibroScan) remains a barrier in identifying high-risk MASLD and is currently underutilized. We evaluate an approach to implementation of […]
Read MoreCategory: Diabetes
1862-P: Medicaid Beneficiaries with Type 1 and Type 2 Diabetes Achieve ADA-Recommended Glycemic Targets Using the MiniMed 780G System
Introduction and Objective: People with diabetes (PWD) who are beneficiaries of Medicaid have worse glycemic outcomes than those with private insurance and are at increased risk for poor clinical outcomes. Barriers to accessing automated insulin delivery (AID) systems include age, complex/extensive prior authorization policies, unclear documentation requirements, and healthcare provider implicit bias about who is […]
Read More2784-LB: Real-World Weight Loss Outcomes among Adults with Type 2 Diabetes Using an AI-Enabled Weight Management Mobile App
Introduction and Objective: Mobile app-based weight management programmes using artificial intelligence (AI) coaching are increasingly used to support lifestyle change in people with type 2 diabetes (T2D), but real-world outcomes remain limited. The aim of this study was to evaluate weight loss among adults with T2D using an AI-enabled weight management app, and to examine […]
Read More2471-P: The Effect of Glucagon on Hepatic Insulin Extraction in Obesity with or without Hepatic Steatosis
Introduction and Objective: Insulin is secreted into the portal vein in response to nutrient ingestion. However, a significant proportion is extracted as it traverses the liver prior to reaching the systemic circulation. The effect of glucagon on hepatic extraction is uncertain. This is particularly germane to situations where postprandial suppression of glucagon is impaired, theoretically […]
Read More2146-P: Gestational Blood Pressure Levels and Risk of Gestational and New-Onset Postpartum Diabetes
Introduction and Objective: Gestational diabetes (GDM) and hypertensive disorders of pregnancy often co-occur and are the leading causes of maternal morbidity. We aimed to examine whether the risks of GDM and new-onset postpartum diabetes (PPDM) increase across gestational blood pressure (BP) categories following the current guidelines with lower thresholds for hypertension (systolic/diastolic BP ≥130/80 mmHg) […]
Read More2466-P: Impact of Body Mass Index and Gender on Fractional Insulin Clearance in Healthy Individuals
Introduction and Objective: The reduction of the insulin Fractional Clearance Rate (FCR) is an early marker of insulin resistance and/or beta-cell disfunction that may be observed before prediabetes arises. Here we aim to investigate whether such reduction is associated with easily measurable anthropometric characteristics, like body mass index (BMI), age and gender.Methods: We studied 204 […]
Read More2210-P: Prototype Tool to Estimate the Probability of Type 1 Diabetes in Adults with New-Onset Diabetes across Four World Regions
Introduction and Objective: Type 1 diabetes in adults is frequently misclassified as type 2, delaying appropriate insulin treatment and leading to worse outcomes. We developed a probability-based tool that combines pre-laboratory clinical characteristics and laboratory results to estimate the likelihood of type 1 vs. type 2 diabetes among adults with new-onset diabetes across four geographic […]
Read More1601-P: Religious and Spiritual Coping among Latinx Parents of Youth with New-Onset Diabetes
Introduction and Objective: There is a need for interventions that respond to cultural strengths and psychosocial burdens of underserved youth with diabetes and their families. Religion/spirituality is a resource that Latinx youth and their parents may use when other resources are unavailable. There is a gap in knowledge about the religious/spiritual experiences and needs of […]
Read More1891-P: Real-World Performance of the MiniMed 780G Advanced Hybrid Closed-Loop System with the Newly Introduced Instinct Sensor in the United States
Introduction and Objective: The MiniMed™ 780G (MM780G) system (Medtronic Diabetes) integrated with the Instinct™ sensor (Abbott Diabetes Care) was recently launched in the United States (U.S.). Designed for use with MiniMed systems, the Instinct™ sensor provides another option for MM780G automated insulin delivery (AID), in addition to the Simplera Sync™ and Guardian™ 4 sensors. The […]
Read More1973-P: Impact of the Inflation Reduction Act on Afrezza Access: A Retrospective Review of TRx Distribution from Baseline Q4 2022 to Q1 2024
Introduction and Objective: The Inflation Reduction Act (IRA), effective January 1, 2023, capped monthly insulin costs for Medicare Part D beneficiaries at $35. Payor restrictions have created barriers to patient access on an innovative Inhaled mealtime Insulin Afrezza driven primarily by high out of pocket costs and prior authorization barriers. This IRA policy shift influenced […]
Read More